CANGRELOR ZUR BEHANDLUNG UND/ODER PRÄVENTION VON SHUNT ODER STENTTHROMBOSE

Patent europeic · EP3641784 · En vigur

Inscripziun en il register

Numer da publicaziun
EP3641784
Numer da la dumonda
EP18737821
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
22-06-2018
Publitgà
29-04-2020
Concedì
04-03-2026
La protecziun finescha il pli tard
21-06-2038
Proxima taxa annuala scadenta
30-06-2027
Classas IPC
A61K 31/7076 (2006.01)
A61P 7/02 (2006.01)
A61P 9/04 (2006.01)
Prioritad
US 201762524102 P 23.06.2017
Dumonda PCT
PCT/EP2018/066817 22.06.2018
Publicaziun PCT
WO2018/234565 27.12.2018
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-07-2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. 11-03-2026

    Represchentant inscrit

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 11.03.2026

  3. 04-03-2026

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 04.03.2026

Partidas

Possessur

Chiesi Farmaceutici S.p.A.

Via Palermo, 26/A, 43122 Parma, IT

Represchentant

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventur

DIACOVO, Thomas G.

43122 Parma, IT

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.